Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
9858 | 1050 | 42.0 | 86% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
151 | 22214 | IMMUNOTHERAPY//DENDRITIC CELLS//CANCER IMMUNOLOGY IMMUNOTHERAPY |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | ADV CELL MOL THER Y | Address | 4 | 67% | 0% | 4 |
2 | SHUNDE PEOPLES HOSP | Address | 4 | 75% | 0% | 3 |
3 | TUMOR VACCINE | Author keyword | 4 | 11% | 3% | 33 |
4 | CYTOKINE GENE TRANSFER | Author keyword | 3 | 43% | 1% | 6 |
5 | ALLOGENEIC VACCINATION | Author keyword | 3 | 100% | 0% | 3 |
6 | IL 2 GENE | Author keyword | 2 | 44% | 0% | 4 |
7 | ALLOGENEIC MAJOR HISTOCOMPATIBILITY COMPLEX | Author keyword | 2 | 67% | 0% | 2 |
8 | ALLOGENEIC MHC | Author keyword | 2 | 67% | 0% | 2 |
9 | DISC HSV | Author keyword | 2 | 67% | 0% | 2 |
10 | THER EUT VACCINES | Address | 2 | 67% | 0% | 2 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | TUMOR VACCINE | 4 | 11% | 3% | 33 | Search TUMOR+VACCINE | Search TUMOR+VACCINE |
2 | CYTOKINE GENE TRANSFER | 3 | 43% | 1% | 6 | Search CYTOKINE+GENE+TRANSFER | Search CYTOKINE+GENE+TRANSFER |
3 | ALLOGENEIC VACCINATION | 3 | 100% | 0% | 3 | Search ALLOGENEIC+VACCINATION | Search ALLOGENEIC+VACCINATION |
4 | IL 2 GENE | 2 | 44% | 0% | 4 | Search IL+2+GENE | Search IL+2+GENE |
5 | ALLOGENEIC MAJOR HISTOCOMPATIBILITY COMPLEX | 2 | 67% | 0% | 2 | Search ALLOGENEIC+MAJOR+HISTOCOMPATIBILITY+COMPLEX | Search ALLOGENEIC+MAJOR+HISTOCOMPATIBILITY+COMPLEX |
6 | ALLOGENEIC MHC | 2 | 67% | 0% | 2 | Search ALLOGENEIC+MHC | Search ALLOGENEIC+MHC |
7 | DISC HSV | 2 | 67% | 0% | 2 | Search DISC+HSV | Search DISC+HSV |
8 | XENOGENEIC CELLS | 2 | 50% | 0% | 3 | Search XENOGENEIC+CELLS | Search XENOGENEIC+CELLS |
9 | TUMOR VACCINES | 2 | 16% | 1% | 11 | Search TUMOR+VACCINES | Search TUMOR+VACCINES |
10 | ALLOGENEIC VACCINE | 2 | 36% | 0% | 4 | Search ALLOGENEIC+VACCINE | Search ALLOGENEIC+VACCINE |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | LASTING ANTITUMOR IMMUNITY | 83 | 57% | 9% | 98 |
2 | REDUCED TUMORIGENICITY | 43 | 50% | 6% | 62 |
3 | IL 2 CDNA | 18 | 89% | 1% | 8 |
4 | ANTIMETASTATIC VACCINATION | 16 | 61% | 2% | 17 |
5 | MURINE MAMMARY ADENOCARCINOMA | 12 | 56% | 1% | 15 |
6 | GAMMA INTERFERON GENE | 11 | 57% | 1% | 13 |
7 | AUTOLOGOUS MELANOMA CELLS | 7 | 29% | 2% | 21 |
8 | ALLOGENEIC MELANOMA CELLS | 6 | 43% | 1% | 10 |
9 | ABROGATES TUMORIGENICITY | 5 | 63% | 0% | 5 |
10 | FACTOR PLUS INTERLEUKIN 4 | 5 | 55% | 1% | 6 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
PARACRINE CYTOKINE ADJUVANTS IN CANCER-IMMUNOTHERAPY | 1995 | 366 | 52 | 48% |
Cytokine-secreting tumor cell vaccines | 2000 | 76 | 53 | 43% |
GM-CSF gene-modifed cancer cell immunotherapies: Of mice and men | 2006 | 51 | 70 | 31% |
GM-CSF-based cancer vaccines | 2002 | 158 | 68 | 25% |
EXPERIMENTAL AND CLINICAL-STUDIES OF CYTOKINE GENE-MODIFIED TUMOR-CELLS | 1994 | 271 | 78 | 46% |
Overview of tumor cell-based vaccines | 2006 | 49 | 108 | 29% |
Immunological gene therapy with ex vivo gene-modified tumor cells: A critique and a reappraisal | 2000 | 55 | 39 | 46% |
Ex vivo gene therapy using cytokine-transduced tumor vaccines: Molecular and clinical pharmacology | 1998 | 69 | 50 | 56% |
GM-CSF gene-transduced tumor vaccines | 2005 | 59 | 66 | 29% |
GM-CSF-based cellular vaccines: a review of the clinical experience | 2002 | 69 | 46 | 26% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | ADV CELL MOL THER Y | 4 | 67% | 0.4% | 4 |
2 | SHUNDE PEOPLES HOSP | 4 | 75% | 0.3% | 3 |
3 | THER EUT VACCINES | 2 | 67% | 0.2% | 2 |
4 | UNIT GENE THER Y | 2 | 50% | 0.3% | 3 |
5 | ONYVAX LTD | 2 | 26% | 0.6% | 6 |
6 | MICROBIOL IMMUNOL MC 790 | 2 | 29% | 0.5% | 5 |
7 | CANC VACCINES | 1 | 50% | 0.2% | 2 |
8 | CLEMMA A HEWITT GENE THER Y | 1 | 100% | 0.2% | 2 |
9 | CLIN COOPERAT GRP UROL TUMORS | 1 | 100% | 0.2% | 2 |
10 | EXPT HEMATOL STEM CELL TRANSPLANTAT | 1 | 50% | 0.2% | 2 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000164237 | TUMOR INFILTRATING LYMPHOCYTES//ADOPTIVE IMMUNOTHERAPY//AUTOLYMPHOCYTE THERAPY |
2 | 0.0000152754 | CYTOSINE DEAMINASE//SUICIDE GENE THERAPY//HERPES SIMPLEX VIRUS THYMIDINE KINASE |
3 | 0.0000119297 | INTERLEUKIN 12//IL 12//IL 12 RECEPTOR |
4 | 0.0000108476 | BELAGENPUMATUCEL L//SRL172//PA MSHA |
5 | 0.0000102086 | CCDC134//TUMOR IMMUN TOLERANCE SECT//ANTIGEN SPECIFIC CTL FUNCTION |
6 | 0.0000098804 | ADENOVIRAL MEDIATED INTERFERON ALPHA//GENE IMMUNE MED//CANC BIOL 173 |
7 | 0.0000097891 | ANTIGEN PROCESSING MACHINERY//BIOQUIM BIOL MOL INMUNOL 3//HLA CLASS I |
8 | 0.0000097862 | CD28//CD80//B7 |
9 | 0.0000095684 | BRAIN TUMOR PROGRAM//GLIOMA IMMUNOTHER Y GRP//GL261 |
10 | 0.0000091845 | CD3 ZETA//ORAL BIOL ORAL MED//ZETA CHAIN |